Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Arielle Elkrief"'
Autor:
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical o
Externí odkaz:
https://doaj.org/article/6b78137517bb4690816d94fa12584591
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 7852-7859 (2023)
Camu camu (CC) is a prebiotic that selectively stimulates growth and activity of beneficial gut microbiota. Work in murine models demonstrated that castalagin, the active compound in CC, preferentially binds to beneficial gut microbiome bacteria, pro
Externí odkaz:
https://doaj.org/article/4e2843d9c0cf44cc9776b479f55445c5
Autor:
Joao V. Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J. Rodig, Emily S. Lebow, Jordan E. Eicholz, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characte
Externí odkaz:
https://doaj.org/article/1cb0d71dba954b7a82afb042b77b3eda
Autor:
Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, Narek Shaverdian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III NSCLC treated with concurrent chemoradiation (cCRT) an
Externí odkaz:
https://doaj.org/article/13b34cc4df014ca0bde4aed8a337931d
Autor:
Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee
Externí odkaz:
https://doaj.org/article/1db67c48820e42a9b021621d9022be62
Autor:
Marion Tonneau, Kim Phan, Venkata S. K. Manem, Cecile Low-Kam, Francis Dutil, Suzanne Kazandjian, Davy Vanderweyen, Justin Panasci, Julie Malo, François Coulombe, Andréanne Gagné, Arielle Elkrief, Wiam Belkaïd, Lisa Di Jorio, Michele Orain, Nicole Bouchard, Thierry Muanza, Frank J. Rybicki, Kam Kafi, David Huntsman, Philippe Joubert, Florent Chandelier, Bertrand Routy
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundRecent developments in artificial intelligence suggest that radiomics may represent a promising non-invasive biomarker to predict response to immune checkpoint inhibitors (ICIs). Nevertheless, validation of radiomics algorithms in independe
Externí odkaz:
https://doaj.org/article/1c9b27366e80483d88227a18e19ca975
Autor:
Marion Tonneau, Alexis Nolin-Lapalme, Suzanne Kazandjian, Edouard Auclin, Justin Panasci, Myriam Benlaifaoui, Mayra Ponce, Afnan Al-Saleh, Wiam Belkaid, Sabrine Naimi, Catalin Mihalcioiu, Ian Watson, Mickael Bouin, Wilson Miller, Marie Hudson, Matthew K. Wong, Rossanna C. Pezo, Simon Turcotte, Karl Bélanger, Rahima Jamal, Paul Oster, Dominique Velin, Corentin Richard, Meriem Messaoudene, Arielle Elkrief, Bertrand Routy
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper ga
Externí odkaz:
https://doaj.org/article/adb7b6925dfe48898a2dcd6d9e30f8ad
Autor:
Bertrand Routy, Corentin Richard, Myriam Benlaïfaoui, Simon Grandjean Lapierre, Nicholas Armstrong, Afnan Al-Saleh, Mélodie Boko, Maxime Jacq, Ian R. Watson, Catalin Mihalcioiu, Arielle Elkrief, Maryam Tidjani Alou, Meriem Messaoudene, Khoudia Diop
Publikováno v:
Microbiology Research, Vol 13, Iss 1, Pp 140-151 (2022)
Fecal microbiome culturomics of a cancer patient treated with immune checkpoint inhibitors led to the identification of a Gram-negative, rod-shaped, obligate anaerobic, non-motile, non-spore-forming bacterium, designated strain kh20T, which was phylo
Externí odkaz:
https://doaj.org/article/133edb383fa74cba9d0a45383600f760
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 813-817 (2021)
Background: Myxofibrosarcoma is a type of soft-tissue sarcoma that is associated with high rates of local recurrence and distant metastases. The first-line treatment for metastatic soft-tissue sarcoma has conventionally been doxorubicin-based. Recent
Externí odkaz:
https://doaj.org/article/c2a79fdfe94643c9b4a4609886cf7341
Autor:
Arielle Elkrief, Petr Kavan, Genevieve Redstone, Luca Petruccelli, Alla'a Ali, Doneal Thomas, Myriam Fernandez, Caroline Rousseau, Olga Aleynikova, Dawn Anderson, Gabriela Ghitulescu, Carol-Ann Vasilevsky, Richard Dalfen, Adrian Langleben, Sender Liberman, Thierry Alcindor
Publikováno v:
BMJ Open Quality, Vol 10, Iss 1 (2021)
Purpose Adjuvant chemotherapy within 56 or 84 days following curative resection is globally accepted as the standard of care for stage III colon cancer as it has been associated with improved overall survival. Initiation of adjuvant chemotherapy with
Externí odkaz:
https://doaj.org/article/3cb07b0e73894aea96963d309933f5e7